Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-13 4:31 pm Purchase |
2024-12-31 | 13G | Allogene Therapeutics, Inc. ALLO |
Arie Belldegrun, M.D. | 12,393,567 5.800% |
2,497,664 (+25.24%) |
Filing History |
| 2024-02-14 4:36 pm Purchase |
2023-12-31 | 13G | Allogene Therapeutics, Inc. ALLO |
Arie Belldegrun, M.D. | 9,895,903 5.800% |
1,037,042 (+11.71%) |
Filing History |
| 2023-02-13 4:31 pm Purchase |
2022-12-31 | 13G | Allogene Therapeutics, Inc. ALLO |
Arie Belldegrun, M.D. | 8,858,861 6.100% |
1,655,613 (+22.98%) |
Filing History |
| 2022-02-17 4:12 pm Purchase |
2021-12-31 | 13G | Kronos Bio, Inc. KRON |
Arie Belldegrun, M.D. | 3,444,889 6.100% |
3,444,889 (New Position) |
Filing History |
| 2022-02-14 3:36 pm Purchase |
2021-12-31 | 13G | Allogene Therapeutics, Inc. ALLO |
Arie Belldegrun, M.D. | 7,203,248 5.000% |
708,755 (+10.91%) |
Filing History |
| 2021-02-12 2:32 pm Sale |
2020-12-31 | 13G | Allogene Therapeutics, Inc. ALLO |
Arie Belldegrun, M.D. | 6,494,493 4.600% |
-859,507 (-11.69%) |
Filing History |